N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-tyrosine>95.0%(T)(HPLC)5g

3-Bromo-6-iodothieno[3,2-b]thiophene, 97%, 5g

1-(1H-1,2,4-triazol-3-yl)piperazine dihydrochloride, 95.0%, 250mg

6-AMINO-1H-INDAZOLE-7-CARBOXYLIC ACID, 95%, 10g

2-Bromoanthracene, 97.0%, 1g

Microliter syringe GASTIGHT® series 1700 Point type 2, 50 µl, 1705 RN, 1 piece

Tetrafluoroterephthalonitrile, 98.0%, 500g

Benzamide, 2-chloro-N-[[2'-[(cyanoamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]-N-[(4-methylphenyl)methyl]-, 98%, 100mg

3,5-Difluoropyridine-4-carboxylic acid, 97.0%, 5g

Crystallization dishes DURAN® with spout, 900 ml, 140 mm, 1 Piece

Tert-butyl (R)-4-(2-aminopropyl)piperazine-1-carboxylate dihydrochloride, 98%, 5g

4,4'-Dihydroxybiphenyl, 95.0%, 1kg

Cyclopentanecarboxylic acid, 97.0%, 1g